Background: Atherosclerosis is a major risk factor for morbidity and mortality. However, epidemiologic data are sparse regarding risk factors for superior mesenteric artery calcification (SMAC), the association between SMAC and disease in other arterial beds, or the independent contribution of SMAC to risk of mortality. The objective of this study was to test the hypothesis that presence and extent of SMAC are associated with cardiovascular disease (CVD) risk factors, calcification in other arterial beds, and both cardiovascular and all-cause mortality, independent of classic risk factors and calcification in other arterial beds.
Subclinical atherosclerosis can be manifested as calcification in several arterial beds, even in individuals who are not traditionally defined as high risk. 1 Whereas calcification in vessels such as the coronary and renal arteries has been shown to have unique risk factors and additional contribution to mortality, 2,3 few data are available for the superior mesenteric artery (SMA). The SMA arises from the abdominal aorta just distal to the celiac trunk and supplies the small intestine, part of the large intestine, and the pancreas. Presumably, SMA calcification (SMAC) represents progression of the same disease process that leads to atherosclerosis and calcified disease in other systemic arterial beds. Indeed, hyperlipidemia, diabetes, and smoking, all of which are wellestablished risk factors for atherosclerosis, are also risk factors for chronic mesenteric ischemia. 4 In this regard, specific radiographic qualitative and quantitative studies would further strengthen these associations or perhaps reveal additional prognostic value of the finding of SMAC for incident cardiovascular events and mortality. This study tested the hypothesis that SMAC presence and extent are positively associated with cardiovascular disease (CVD) risk factors, calcified atherosclerosis in other arterial beds, and both cardiovascular and allcause mortality, even after adjusting for risk factors and presence of systemic atherosclerotic disease.
METHODS
Subjects. From March 1, 2000, to July 3, 2003, 5156 healthy individuals without known CVD presented for preventive medicine services at a university-affiliated disease prevention center in San Diego, California. Of these, 4300 had complete survey and vascular calcification data and were included in our analysis. Subjects were self-referred or referred by a physician to obtain preventive health information and testing. Subjects completed a health history questionnaire that included information on history of hypertension, diabetes, high cholesterol, smoking (ever or never smoker), medications, and family history of coronary heart disease (CHD). The protocol for this study was approved by the Human Research Protection Program at the University of California, San Diego, and all subjects gave informed consent.
Laboratory measurements. Total, high-density, and low-density cholesterol and glucose measurements were obtained by fingerstick using the Cholestech LDX system (Cholestech, Hayward, Calif). Individuals with a total/ high-density lipoprotein cholesterol ratio >5 or who reported using a medication to treat high cholesterol levels were classified as dyslipidemic. Diabetes was defined by use of prescribed diabetes medications at the time or a random glucose level >200 mg/dL. While seated, blood pressure was measured in the right arm by automated oscillometry after 5 minutes at rest. Hypertension was defined as a systolic pressure or diastolic pressure >140 or 90 mm Hg, respectively, or a self-reported history of physician-diagnosed hypertension and current use of an antihypertensive medication.
Imaging. Noncontrast-enhanced computed tomography imaging was conducted using an Imatron C-150 scanner (General Electric, San Francisco, Calif). Images for each arterial bed were obtained from the base of the skull to the pubic symphysis. Each bed was obtained by a distinct scan of the segment in question by using slice thicknesses of 3 mm for the coronary bed, 5 mm for the thorax, and 6 mm through the neck, abdomen, and pelvis. Imaging of the heart, thorax, and abdomen was conducted during separate breath holds at 50% maximal inspiration. These images were subsequently analyzed for the presence and extent of vascular calcification in the coronary arteries, thoracic aorta, abdominal aorta, SMA, celiac trunk, and iliac arteries. Quantitative calcium scores for each arterial bed were determined according to the method described by Agatston et al. 5 Data on a subgroup of these individuals have been previously reported. 3 The SMA was identified at its anterior takeoff from the aorta and was tracked caudally until no longer discernible. In cases in which calcification extended from the aorta into the ostia of the SMA, a vertical plane simulating the wall of the aorta traversing the ostium was drawn to approximate the lumen of the aorta. Any calcification medial to the plane was excluded from the calculation as SMAC.
Mortality data. All-cause mortality was determined up to December 31, 2010, using Social Security Death Index searches and the National Death Index. Date and cause of death were extracted from death certificates and by the National Death Index search. The cause of mortality was ascertained by physician adjudicators (M.A.A., M.H.C.).
Statistical analysis. Baseline characteristics stratified by SMAC absence vs presence were examined using c 2 analysis or Welch unequal variances t-test as appropriate. Proportions of calcification in other arterial beds were compared between those with and without SMAC using c 2 analysis. Age-and sex-adjusted Spearman rank correlation was used to determine partial coefficient correlations of the extent of calcification (represented as log 10 [score þ 1]) between the SMA and the non-SMA arterial beds included in the analysis (the thoracic aorta, abdominal aorta, coronary arteries, iliac arteries, and celiac trunk).
As the prevalence of SMAC did not exceed 10% in our study sample, a multiple logistic regression model was used to determine risk factor associations for SMAC presence. The risk factors included were age, sex, body mass index (BMI), body fat percentage (BF%), dyslipidemia, any smoking, hypertension, diabetes, and family history of CHD. The model was then further adjusted for calcification in five other arterial beds (abdominal aorta, thoracic aorta, coronary arteries, iliac arteries, and celiac trunk). A similar analysis was performed using multiple linear regression, with SMAC extent (represented as log 10 [SMAC score þ 1]) as the outcome variable. In a separate logistic regression model, SMAC presence was used as a predictor for systemic calcified atherosclerosis, defined as having calcification in all five of the aforementioned non-SMA arterial beds. The model was first adjusted for age and sex and then for all risk factors. A similar analysis using SMAC extent rather than presence as a predictor was performed.
Survival analysis was performed using Kaplan-Meier curves and Cox regression models. SMAC presence and Recommendation: This study suggests that calcification of the superior mesenteric artery is associated with cardiovascular risk factors and is an independent risk factor for cardiovascular-related and allcause mortality.
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SMAC extent were used in separate models as the exposure variable. Each model was adjusted for age and sex, then CVD risk factors, then calcification in other arterial beds (to account for collinearity, this was represented as the number of other arterial beds with calcium score > 0, ranging from 0 to 5).
The level of significance used in this study was P < .05. All statistical analysis was performed using SPSS Statistics version 22 (IBM Corp, Armonk, NY).
RESULTS
Baseline characteristics. The average age was 56 years; 43.7% (1877/4300) were women, and 6.7% (290/4300) had SMAC. Among those with SMAC, the median Agatston score was 51.3 (interquartile range, 22.0-112.3). Those with SMAC were likely to be older (69.7 vs 55.1 years; P < .001) and male (73.1% vs 55.1%; P < .001). They also tended to have hypertension (38.6% vs 21.3%; P < .001), diabetes (10.0% vs 3.1%), history of smoking (65.2% vs 42.5%), and higher BF% (31.4% vs 29.7%; P < .001; Table I ). Those with SMAC had, on average, 3.9 other arterial beds with calcification present compared with 1.9 other beds in those without SMAC. Moreover, 21.4% of those with SMAC had calcification in all five other beds compared with 1.1% of those without SMAC (Table I) . Only two subjects had SMAC without calcification in any other bed. Among the entire sample, calcification in the coronaries was most common (55.2%), followed by the abdominal aorta (54.6%), then the iliacs (49.4%; Table II) . Those with SMAC had a higher prevalence of calcification in each arterial bed compared with those without SMAC. The partial correlation coefficients between logtransformed calcium scores in different arterial beds are shown in Table III . The extent of SMA calcification correlated most with that of the celiac trunk (correlation coefficient ¼ 0.306; P < .001) and thoracic aorta (0.260; P < .001) and least with that of the coronary arteries (0.170; P < .001).
Risk factors. In a fully adjusted multiple logistic regression model (Table IV) , age per 1-year increment (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06-1.11), dyslipidemia (OR, 1.38; 95% CI, 1.01-1.88), and any smoking (OR, 1.60; 95% CI, 1.20-2.14) were significantly associated with the presence of SMAC, whereas female sex was inversely associated (OR, 0.56; 95% CI, 0.33-0.93). BMI, BF%, hypertension, diabetes, and family history of CHD were not significantly associated with SMAC presence. Using a multiple linear regression model, the risk factors significantly associated with an increase in SMAC extent, expressed as % change (using the relation % change ¼ 100*[e b coefficient À 1]), were age (% change, 0.80%; 95% CI, 0.60%-0.90%), male sex (4.97%; 95% CI, 0.30%-9.43%), any smoking (4.08%; 95% CI, 1.41%-6.72%), and diabetes (7.14%; 95% CI, 0.20%-14.57%; Table V) ; BMI, BF%, dyslipidemia, hypertension, and family history were not significantly associated with SMAC extent.
Systemic calcified atherosclerosis. In the study sample, 1058 subjects did not have calcification in any of the five other arterial beds; of these, only 2 (0.2%) had SMAC. Conversely, 105 subjects had calcification in all five other arterial beds, and of these, 62 (59.0%) also had SMAC. To further investigate the relationship between the extent of calcified atherosclerosis and the presence of SMAC, advanced atherosclerosis was defined as having calcification in all five other arterial beds. Separate logistic regression models adjusted for risk factors showed that SMAC presence conferred a 6.02 (3.76-9.66) higher odds for advanced atherosclerosis, whereas a per-unit increase in log (SMAC score þ 1) was associated with a 2.54 (95% CI, 2.009-3.201) higher odds.
In a linear regression model using number of arterial beds with calcification as a continuous dependent variable and SMAC presence as the independent variable, SMAC presence was associated with 2.13 more calcified beds (95% CI, 1.95-2.30). When adjusted for all risk factors, effect size was attenuated to 0.65 more calcified beds (95% CI, 0.51-0.79).
Mortality. During a median follow-up time of 9.4 years, there were a total of 234 deaths, of which 76 were determined to be of a cardiovascular cause (Table I) . Kaplan-Meier curves for overall survival (Fig 1) and cardiovascular survival (Fig 2) demonstrated significant There is a significant difference in cumulative overall survival between those with and without SMAC (log-rank test, P < .001). Note that the y-axis begins at 0.5.
Fig 2.
Kaplan-Meier curve for cardiovascular survival among those with or without superior mesenteric artery calcification (SMAC). There is a significant difference in cumulative cardiovascular survival between those with and without SMAC (log-rank test, P < .001). Note that the y-axis begins at 0.5.
and each log-increase in SMAC þ 1 (HR, 1.25; 95% CI, 1.06-1.48) were both significantly associated with an increased risk of total mortality. For cardiovascular mortality, SMAC presence was associated with an HR of 1.61 (95% CI, 0.94-2.74) after full adjustment; each log-increase in SMAC þ 1 was associated with an HR of 1.31 (95% CI, 1.01-1.71) after full adjustment.
DISCUSSION
In this study of a relatively large community-based sample, we tested the hypothesis that SMAC is associated with CVD risk factors, atherosclerosis in other arterial beds, and an increase in both cardiovascular and allcause mortality. The findings indicate that those with SMAC have significantly higher levels of calcified atherosclerosis in other arterial beds and a significantly higher risk for incident CVD and total mortality compared with those without SMAC.
Of the risk factors included in this analysis, age and history of any smoking were associated with both the presence and extent of SMAC. Dyslipidemia was associated with presence of SMAC but not with extent. On the other hand, whereas diabetes conferred the highest increase in risk for SMAC extent, the adjusted association with SMAC presence was not significant. The other classic risk factors included in the analysis, notably hypertension, were not significantly associated with either SMAC presence or extent. This is contrary to prior findings of hypertension significantly associated with calcification in the other mesenteric arteries (ie, abdominal aorta and renal arteries). 3, 6 That SMAC is associated with a unique set of risk factors compared with calcification in coronary arteries 7 and nearby arterial beds may be suggestive of a separate pathophysiologic process and may further inform the risk of other forms of vascular disease. Our findings suggest the SMAC presence is associated with increased risk of calcification of any of the other arterial beds. Both SMAC presence and extent also confer a significantly higher risk of calcified atherosclerosis in all five of these beds. More specifically, the overall prevalence of SMAC in our study sample was 6.7%, and only two subjects had SMAC without also having any calcification in any other bed, whereas more than half of the subjects with calcification in all five other beds had SMAC. Taken together, these findings suggest that SMAC occurs late in subclinical atherosclerotic disease. It would be interesting to see whether SMAC is of prognostic value or can predict the onset of symptomatic disease, such as chronic mesenteric ischemia or acute coronary syndromes. It has been shown, though, that significant disease of mesenteric vessels, as determined by ultrasound, does not necessarily indicate symptomatic mesenteric ischemia. 8 Similar to earlier findings for renal artery calcium in this cohort, 9 SMAC was associated with increased total and CVD mortality. It is possible that SMAC is a marker for advanced and systemic atherosclerotic disease, and our findings affirm that presence and extent of disease in the SMA correlate with that in other arterial beds. However, given that SMAC remained significant after adjusting for risk factors and calcification in other arterial beds, alternative explanations should be entertained, for example, that there is residual confounding for the association of SMAC with mortality or that SMAC may be a proxy for pathophysiologic processes separate from those leading to atherosclerotic disease, as was posited in our previous discussion about the unique risk factors for SMAC. Further studies would be needed to examine these associations in greater detail. Because we present the results of an observation study and there are sparse data on the epidemiology of SMAC, we recommend neither elective whole-body screening computed tomography scans nor specific imaging to assess for SMAC at this time. However, the incidental finding of SMAC on a noncontrast-enhanced computed tomography scan obtained for another indication could be used to inform risk factor management.
Strengths of this study include a large sample size and availability of imaging and data pertaining to other arterial beds. Also, the mortality outcomes were collected systematically and adjudicated by a physician panel. Limitations to our study include the large proportion of self-referred individuals, likely to be of higher socioeconomic status on average, which may limit the generalizability of our results. Additional history, such as abdominal or gastrointestinal complaints, was not collected. For our analysis, the definition of hypertension, dyslipidemia, and diabetes included ongoing pharmacologic treatments (to include statins, beta blockers, and angiotensin-converting enzyme inhibitors). However, specific medications or dosages were not collected for each participant.
CONCLUSIONS
SMAC presence is associated with a unique set of traditional risk factors for CVD, raising the possibility of differing pathophysiologic processes contributing to the development or progression of SMAC. The presence of any SMAC was associated with greatly increased odds for calcification in all other arterial beds and suggests that calcification of the SMA occurs with subclinical yet widely manifested systemic atherosclerotic disease. Finally, SMAC was significantly associated with increased total and cardiovascular mortality even after adjustment for risk factors and calcification in other arterial beds. Further research may help clarify whether SMAC itself may be an independent risk factor for increased mortality or whether SMAC serves as a proxy for other risk factors that independently contribute to mortality. 
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